Concepedia

Christopher Carlson

CC

27

Publications

2.4K

Citations

19

H-Index

1983

Active since

Affiliations

Eli Lilly (United States)(Current)

Rutgers, The State University of New Jersey

South Dakota Department of Health

South Dakota State University

California Pacific Medical Center

Christopher Carlson is an author at Eli Lilly (United States) specializing in medicine, neuroinflammation, and pharmacology.

Top concepts

Publications per year

1983–2018

27

Publications

27

Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease

Lawrence S. Honig, Bruno Vellas, Merçé Boada et al. · New England Journal of Medicine · 2018 · 1K citations · Full text

Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients

Eric Siemers, Karen Sundell, Christopher Carlson et al. · Alzheimer s & Dementia · 2015 · 362 citations · Full text

Effects of Antipsychotic Drugs on Ito, INa, Isus, IK1, and hERG: QT Prolongation, Structure Activity Relationship, and Network Analysis

William Crumb, Sean Ekins, R. Dustan Sarazan et al. · Pharmaceutical Research · 2006 · 89 citations

, , +12

Amantadine for weight gain associated with olanzapine treatment

Walter Deberdt, Andrew Winokur, Patrizia Cavazzoni et al. · European Neuropsychopharmacology · 2004 · 85 citations

, , +5

Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab

Christopher Carlson, Wahiba Estergard, Joonmi Oh et al. · Alzheimer s & Dementia · 2011 · 76 citations

Rows per page

1–5 of 27